Conjunctival repair after glaucoma drainage device exposure using collagen-glycosaminoglycane matrices

Conjunctival defects after penetrating glaucoma surgery, e.g. trabeculectomy or insertion of episcleral glaucoma drainage devices, are rare but severe complications. The defects often lead to leakage and contact between the anterior chamber and surrounding surfaces with the risk of subsequent carry-over of bacteria, blebitis and endophthalmitis [1‐5].

In the case of trabeculectomy, especially after use of antimetabolites such as mitomycin-C (MMC) and 5-fluoruracile (5-FU), conjunctival defects can even occur a long time after surgery. Antimetabolites, which are very useful for prevention of scarring, affect wound healing processes and lead to the formation of thin-walled blebs [6].

After implantation of an episcleral glaucoma drainage device (GDD, e.g. the non-valved Baerveldt (Advanced Medical Optics, USA) or the valved Ahmed (New World Medical, USA) etc.), complications such as erosion of the tube (GDD-specific) or even the plate of the implant through the conjunctiva occur in 2–7% cases [1‐5]. As with late bleb leakage after trabeculectomy, erosion of the conjunctiva exposing the tube of the GDD makes revision surgery necessary [7]. Erosion of the conjunctiva on top of the tube or the implant is more frequent in eyes with a history of multiple intraocular surgeries.

To repair erosion of the conjunctiva, a patch is usually placed on top of the tube and the conjunctiva is closed above this patch. Due to the surrounding scar tissue and the fragile structure of the frequently inflamed tissue around the tube, specialist knowledge and skill are required to achieve long-lasting wound closure in conjunctiva surgery. As reported in a case report [8], we favour a combination of re-fixation of the tube to the sclera with prior lateral displacement of the tube, followed by patching of the implant with a slice of a biodegradable implant (ologen™ implant, Aeon Astron Corporation, The Netherlands) in combination with conjunctival advancement. The aim of the lateral displacement of the tube is to avoid mechanical problems between the tube and lid margin at the previous point of conjunctival erosion, which could trigger repeated conjunctival erosion.

Since only a small number of patients suffer from conjunctival erosion after glaucoma drainage device surgery (2–7%) [1‐5], we present a case-series of just eight patients who underwent such surgery. We hereby focus not only on the surgical success in covering the defect, but also on intraocular pressure, antiglaucomatous medication, visual acuity and the need for further surgical interventions.

In most cases the buttonholes occurred directly adjacent to the lid margin. Patient characteristics are given in Table 1; showing that the patients had multiple preoperated eyes. Erosion of conjunctiva occurred after a minimum of one and a maximum of 70 months after glaucoma drainage device surgery with a mean of 25.1 ± 30.8 months. We could not detect any ologen™ specific side-effects such as allergy or translocation of the implant on postoperative follow-up visits. No severe postoperative complications were detected and conjunctiva remained healthy and closed on follow-up.

The course of intraocular pressure changes and medication score is shown in Table 2. The mean follow-up time was 26.8 ± 9.0 months. Further glaucoma surgery was necessary in three cases: in one case (patient #2) an additional glaucoma drainage device was used, while in two cases (patient #4 & #6) additional cyclophotocoagulation was applied.

Glaucoma drainage device surgery is a useful adjunct in the treatment of refractory glaucoma despite having a few serious complications [1, 11‐13]. As a consequence of the results of the TVT study [14, 15], glaucoma drainage device surgery is now being used more frequently than in the past and at an earlier stage (typical situation: Pseudophakic eyes with one or two failed trabeculectomies). Since this surgical method is now carried out more frequently, an increasing number of typical side-effects should be taken into consideration. One such complication is thinning of the conjunctiva directly above the tube with complete erosion of the overlying tissue [5]. This may result in leakage and is always an indication for revision surgery, as this entrance gate is a potential source of endophthalmitis [7].

The exact mechanism of conjunctival erosion remains unclear since, as far as could be seen, the implants and the tubes were correctly positioned. The buttonholes are probably formed either due to mechanical stress at the lid margin or due to the gap between the tube and sclera posterior to the scleral flap arising through the architecture of the glaucoma drainage devices near the basal plate.

To prevent conjunctival erosion, the tube should be patched during primary surgery and the patch covered with conjunctiva. The tube can be patched either with a scleral flap or with bovine pericardium, human sclera or other materials. The use of patched tubes has decreased the exposure rate from 30% to less than 5% [5]. In our case series all tubes were patched with a scleral flap in primary surgery.

Should a penetrating defect in the conjunctiva nevertheless occur during follow-up, it can be difficult to achieve closure of conjunctiva. A few methods for closing these defects in the conjunctiva have been described previously: For direct suture of the defect and use of conjunctival autografts, the results in literature show different success rates: A simple conjunctival closure is inadequate [16]. Reports on conjunctival autografts and conjunctival closure with a patch graft provided better results (Success rates: acellular human dermis patch graft: 83%; autologous scleral lamellar graft: 100%) [5, 16]. Also good results have been reported with amniotic membranes and additional application of autologous serum in a few cases of conjunctival erosion (Three cases; 100% success; follow-up: 6–30 months) [17].

Preliminary studies on bioengineered, biodegradable implants suggest that a porous collagen-glycosaminoglycane matrix (CGM; ologen™) will reduce conjunctival contraction and promote formation of an almost normal subconjunctival stroma [18‐20]. Moreover, the use of the ologen™ implant was also described in primary glaucoma drainage device surgery as a patch with a good success rate [21]. This led us to try CGM in a single case of revision surgery after buttonhole formation on top of the drainage device tube [8]. After use of a total of eight CGM in revision surgery, we can confirm the persistent closure of conjunctival defects in all cases. No severe postoperative complications or CGM-specific side-effects were detected in our study series.

Except the patching of the tube with an ologen™ implant, the lateral displacement of the tube also appears to be decisive in our approach. This prevents the previously damaged conjunctiva from contact with the tube.

Our case series shows that the described method with lateral displacement of the tube and patching with CGM is a possible alternative in revision surgery for repair of eroded conjunctiva overlying the tube of the glaucoma drainage device. Possible positive effects of the CGM are the avoidance of direct contact between the conjuctiva and the tube and the fact that CGM acts as a wound healing scaffold for structurally more normal tissue rather than structurally deficient scar tissue. Moreover, CGM probably minimizes movement of the conjunctiva in relation to the tube thus facilitating wound healing.